CAS: 1048007-93-7; N-(4-Methyl-3-((4-(Pyridin-3-yl)Thiazol-2-yl)Amino)Phenyl)-4-((4-Methylpiperazin-1-yl)Methyl)Benzamide Methanesulfonate
该化合物是一种针对c-Kit,PDGFR和Lyn kyases的选择性抗抑郁性顺质抑制剂,主要调查其在肿瘤学和炎症(包括螺旋细胞介质疾病)中的治疗潜力,包括血管细胞障碍.甲基盐形式提高了溶解性和生物利用率,促进了配方开发.Masitinib对其目标具有高度的特性,与更广泛的动脉抑制剂相比,尽可能减少目标外的影响.临床和临床研究表明,在诸如高级肌肉细胞病症,亚麻风性横向硬质病(ALS)和某些癌症等条件下,其疗效.其特征精细的药用植物基因特征支持了可预测的剂量疗法.该化合物作为高纯度的晶状固体供应,确保研究和药物应用的一致性.稳定和处理符合标准的实验室规程.
- 英文名称N-(4-Methyl-3-((4-(Pyridin-3-yl)Thiazol-2-yl)Amino)Phenyl)-4-((4-Methylpiperazin-1-yl)Methyl)Benzamide Methanesulfonate
- 中文名称4-[(4-甲基-1-哌嗪基)甲基]-N-[4-甲基-3-[[4-(3-吡啶基)-2-噻唑基]氨基]苯基]-甲基磺酰基苯胺
- IUPAC名称N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate
- 其它别名Masitinib Mesilate
- CAS编号1048007-93-7
- MFCD编号:MFCD12546334
- FDA UNII编号:ZK89EG3A18
- 分子式:C29H34N6O4S2分子量:594.76
- 产品CID: 86950
- 同类组份化合物CAS1048007-93-7 (mesylate)790299-79-5 (free base)
- 产品分类生物化工 → 生化试剂 → 激动剂抑制剂
MSDS等安全信息
上下游产品
CAS号790299-79-5 马赛替尼 | CAS号75-75-2 甲基磺酸合成工艺路线路线简述
📜马赛替尼,甲烷磺酸 以 甲醇 用作溶剂,化学反应 13.0H,以8.5 G的收率获得4-[(4-甲基-1-哌嗪基)甲基]-N-[4-甲基-3-[[4-(3-吡啶基)-2-噻唑基]氨基]苯基]-甲基磺酰基苯胺
参考文献: Crystalline Form Of Masitinib[fr] Forme Cristalline De Masitinib
标题: Crystalline Form Of Masitinib[fr] Forme Cristalline De Masitinib
摘要:本发明涉及马西替尼甲磺酸盐的多晶型形式,其制备过程,包含它的制药组合物及其医学用途.
专利信息
专利号:AU-2008214679-A1
优先权日:2007-02-13
标题 :Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
专利号:US-2010121063-A1
优先权日:2007-02-13
标题:Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
专利号:US-8153792-B2
优先权日:2007-02-13
标 题 :Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
专利号:BR-PI0807626-B1
优先权日:2007-02-13
标 题 :PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS
专利号:US-2012196871-A1
优先权日:2007-02-13
标题:Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
专利号:CA-2677586-A1
优先权日:2007-02-13
标题 :Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Devine L, Polzin DJ. Presumed masitinib-induced nephrotic syndrome and azotemia in a dog. Can Vet J. 2016 Jul;57(7):752-6.
2: Grant J, North S, Lanore D. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours. J Small Anim Pract. 2016 Jun;57(6):283-90. doi: 10.1111/jsap.12480. Epub 2016 May 2. doi: 10.1016/j.rvsc.2014.02.001. Epub 2014 Feb 11. doi: 10.1016/j.critrevonc.2013.12.011. Epub 2013 Dec 17. Review. doi: 10.1111/vco.12053. Epub 2013 Jul 12. doi: 10.1097/CAD.0b013e32836002ba. doi: 10.1111/j.1476-5829.2012.00335.x. Epub 2012 May 18. doi: 10.1111/j.1939-1676.2011.0687.x. Epub 2011 Feb 11.
合成参考文献
参考文献:10.1016/s0022-3565(25)30558-6
摘要:Smith RJ, Fisher JW. Neutral protease activity and erythropoietin production in the rat after cobalt administration. The Journal of Pharmacology and Experimental Therapeutics. 1976 Jun;197(3):714–22. doi: 10.1016/s0022-3565(25)30558-6.
📝 需求与反馈
尽可能描述清楚需求与问题信息
